All In Biotech

Drug Trial Radar · NCT05367089

The Effect of Medical Grade Honey Formulation (L-Mesitran) Administration on Recurrent Vulvovaginal Candidiasis Symptoms

A Randomized Controlled Trial: the Effect of a Medical Grade Honey Formulation (L-Mesitran) on Clinical Symptoms of Recurrent Vulvovaginal Candidiasis

Last checked: Nov 20, 2026Latest source record: May 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 252 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

252

Planned (sponsor's estimate)

Start

Aug 22, 2022

Primary completion

Apr 22, 2026

Study completion Apr 22, 2027

Sponsor

Lead sponsor
Maastricht University Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Zuyderland Medical Centre
First posted
May 10, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the study is to investigate the efficacy of Fluconazol versus L-Mesitran in the treatment of patients with recurrent vulvovaginal candidiasis. Vaginal swabs will be analyzed after 1, 6 and 12 months. The study ends after 252 included patients completed the study.

Conditions

  • Candidiasis, Vulvovaginal
  • Recurrent Candidiasis of Vagina

Interventions

  • FluconazoleDrug

    Way of administration: oral capsules. One capsule at the same day of the week. Dosage: As treatment for active RVVC- in the first week on day 1 one capsule 150 mg Fluconazole, on day 4 one capsule 150 mg Fluconazole and on day 7 one capsule 150 mg Fluconazole. As prophylaxis to prevent a new RVVC episode: one capsule Fluconazol 150 mg per week for a duration of 6 months.

  • L-MesitranDevice

    Way of administration: intra-vaginal application using an applicator. Dosage: As treatment for active RVVC - Single daily application (5 grams) for 1 month. As prophylaxis to prevent a new RVVC episode: Single weekly (5 grams) application for 5 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. vaginal swabTime frame: 1 month
  2. vaginal swabTime frame: 6 months
  3. vaginal swabTime frame: 12 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Zuyderland Medical Centre

    Heerlen, Netherlands · Recruiting

  • MaastrichtUMC

    Maastricht, Netherlands · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.